Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Presence of active clinical synovitis in at least 2 joints, 1 of which must have been a small joint, for a minimum of 8 weeks prior to screening
Onset of persistent symptoms ≤ 2 years prior to screening
Positive test result for anticyclic citrullinated peptides 2
Methotrexate naive or with minimum exposure to methotrexate, defined as no more than 10 mg/week for ≤4 weeks and no methotrexate dose for 1 month prior to screening visit
Biologic naive, including no treatment with an investigational biologic prior to screening
Disease Activity Score 28 based on C-reactive protein score ≥3.2 at screening
Withdrawal from any treatment with chloroquine, hydroxychloroquine, and/or sulfasalazine (wash-out) for a minimum of 28 days prior to randomization
If receiving oral corticosteroids, on a stable low dose (≤ 10 mg/day prednisone equivalent) for at least 4 weeks
Able to undergo magnetic resonance imaging
You may not be if
Meeting diagnostic criteria for other rheumatic disease (eg, lupus erythematosus)
Treatment with an intravenous, intramuscular, or intraarticular corticosteroid within 4 weeks prior to randomization
Scheduled for or anticipating joint replacement surgery
Presence of concomitant illness likely to require systemic glucocorticosteroid therapy during the study, in the opinion of the investigator
History of malignancy in the last 5 years
Any serious bacterial infection within the last 3 months not treated or resolved with antibiotics, or any chronic or recurrent bacterial infection
At risk for tuberculosis
Evidence of active or latent bacterial or viral infection at the time of potential enrollment, including human immunodeficiency or herpes zoster virus or cytomegalovirus that resolved less than 2 months prior to enrollment
Clareo Health | Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
